Schizophrenia
Blog, DRUG NEWS, PHARMA MARKET, PHARMA TRENDS: Upcoming Drugs

Minerva (NASDAQ: NERV): New Drug For Schizophrenia Under Review In February 2024

  Minerva Neurosciences’ Roluperidone Under FDA Review: A Potential Game-Changer for Schizophrenia Treatment Minerva Neurosciences Inc., a clinical-stage biopharmaceutical company, […]

, ,